Cassava Sciences, Inc. (SAVA)

27.22 +0.22 (+0.82%) As of 03:49PM EDT. Market open.

Cassava Sciences, Inc.

6801 N. Capital of Texas Highway
Suite 300 Building 1
Austin, TX 78731
United States
512 501 2444
https://www.cassavasciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 29

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Eric J. Schoen	Chief Financial Officer	460k	N/A	1968
Mr. R. Christopher Cook	Senior VP, Company Secretary & General Counsel	425k	N/A	1964
Mr. Remi Barbier	Executive Officer	1.2M	598.57k	1960
Dr. James W. Kupiec M.D.	Chief Medical Officer	435k	N/A	1953
Dr. George Thornton Ph.D.	Senior Vice President of Technology	N/A	N/A	N/A
Mr. Michael Zamloot	Senior Vice President of Technical Operations	N/A	N/A	N/A
Dr. Michael Marsman Pharm.D.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Dr. Lindsay H. Burns Ph.D.	Senior Vice President of Neuroscience	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Corporate Governance

Cassava Sciences, Inc.’s ISS Governance QualityScore as of September 1, 2024 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.